Abstract
IL-1β-converting enzyme (ICE, caspase-1) is the prototype of a family of cysteine proteases termed caspases, sharing the active site cysteine and aspartate binding clefts. The biological function of caspase-1 was originally thought to be restricted to the maturation process of IL-1β, a central mediator in the cytokine network. Proteolytic maturation of the inactive, 33-kD IL-1β precursor (proIL-1β) into the 17-kD, biologically functional form results from cleavage at the Asp116-A1a117 site [1,2]. However, recent studies revealed that caspase-1 mediates processes relevant to immune and inflammatory reactions, in addition to IL-1β activation. The enzyme has been implicated in the activation of another inflammatory cytokine, IL-18, originally termed IFN-γ inducing factor (IGIF). Similar to IL-1β, IL-18 is expressed as an inactive precursor (24 kD), requiring proteolytic conversion via caspase-1 into the active, 18-kD form. The biological function of IL-18 was originally thought to be restricted to the induction of another inflammatory cytokine, IFN-, which has well-known roles in inflammation and Thl immune responses. However, recent work indicated a much broader role for IL-18 in immunity and inflammation, mediating the expression of other proinflammatory cytokines, certain chemokines, and Fas ligand. In addition to the activation of proinflammatory mediators, caspase-1 is the prototype of a family of enzymes implicated in the control of apoptosis. Although the exact function of caspase-1 is controversial, this enzyme may participate in programmed cell death. In recent years ICE has been recognized as a member of the growing family of intracellular cysteine proteases that share sequence homology with Ced-3, a nematode gene involved in the execution phase of apoptosis [3–5]. The mammalian counterpart of the Ced-3 gene products includes at least 14 different endoproteases that have been renamed caspases to denote cysteine proteases acting after an aspartic acid residue. Caspase-1, which has the greatest specificity for cleaving proIL-β, denotes the original ICE (both terms are often used interchangeably).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 2095.
Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768.
Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443.
Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312.
Alnemri ES, Livingston DJ, Nicholson DW,et al. Human ICE/CED-3 protease nomenclature. Cell 1997; 87: 171.
Dinarello CA, Margolis NH. Stopping the cuts: the recently discovered enzymes that process the precursors of inflammatory cytokines are good targets for the design of new anti-inflammatory therapeutic agents. Curr Biol 1995; 5: 587.
Elliott SN, McKnight W, Cirino G., Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524.
Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. 1995. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995; 96: 2711.
Fiorucci S, Santucci L, Federici B, et al. Nitric oxide (NO)-releasing NSAIDs inhibit interleukin-lß converting enzyme (ICE)-like cysteine proteases and protect endothelial cells from apoptotosis induced by TNFa. Aliment Pharmacol Ther 1999; 13: 421.
Fiorucci S, Antonelli E, Santucci L, et al. Gastrointestinal safety of NO-derived aspirin is related to inhibition of ICE-like cysteine proteases. Gastroenterology 1999; 116: 1089.
Fiorucci S, Santucci L, Antonelli E, et al. 2000. NO-aspirin protects from T-cell mediated liver injury by inhibiting caspase-dependent processing of Thl-like cytokines. Gastroenterology 2000; 118: 404.
Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810–816.
Fiorucci S, Santucci L, Cirino G, et al. IL-lbeta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J Immunol 2000 Nov 1; 165 (9): 5245–54.
Dimmeler S, Haendeler J, Nehls M, Andreas M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997; 185: 601.
Kim Y-M., Talaninian RV, Li J, Billiar TR. Nitric oxide prevents IL-1 ß and IFNy-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-lß converting enzyme). J Immunol 1998; 161: 4122.
Young-Myeong K, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997; 272: 3 1138.
Rossig L, Fichtlscherer B, Breitschopf K, et al. Nitric oxide inhibits caspase 3 by S-nitrosation in vivo. J Biol Chem 1999; 274: 6823.
Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-y inducing factor. J Leukoc Biol 1998; 63: 658.
Okamura H, Nagata K, Komatsu T, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995; 63: 3966.
Puren AJ, Fantuzzi G, Gu Y, Su MS-S, Dinarello CA. Interleukin-18 (IFN gamma-inducing factor) induces IL-8 and IL-lbeta via TNF alpha production from non-CD14+ human blood mononuclear cells. J Clin Inv 1988; 101: 711.
Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-y-inducing factor and regulates LPS-induced IFN-y production. Nature 1997; 386: 619.
Gu Y, Kuida K, Tsutsui H, et al. Activation of interferon-gamma inducing factor is mediated by interleukin-lbeta converting enzyme. Science 1997; 275: 206.
Li P, Allen H, Banerjee S, Franklin S, et al. Mice deficient in interleukin-1 converting enzyme (ICE) are defective in production of mature interleukin-lbeta and resistant to endotoxic shock. Cell 1995; 80: 401.
Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. N Eng J Med 1993; 329: 2002.
Rossig L, Fichtlscherer B, Breitschopf K, et al. Nitric oxide inhibits caspase 3 by S-nitrosation in vivo. J Biol Chem 1999;
Kolb H, Kolb-Bachofen V. Nitric oxide in autoimmune disease: cytotoxic or regulatory meditor? Immunol Today 1998; 19: 556.
Margolin N, Raybuck SA, Wilson KP, et al. Substrate and inhibitor specificity of interleukin- 1 -converting enzyme and related caspases. J Biol Chem 1997; 272: 7223.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Fiorucci, S., Antonelli, E. (2001). NO-Releasing NSAIDs Modulate Cytokine Secretion. In: Samuelsson, B., Paoletti, R., Folco, G.C., Granström, E., Nicosia, S. (eds) Advances in Prostaglandin and Leukotriene Research. Medical Science Symposia Series, vol 16. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9721-0_33
Download citation
DOI: https://doi.org/10.1007/978-94-015-9721-0_33
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5881-2
Online ISBN: 978-94-015-9721-0
eBook Packages: Springer Book Archive